A universal CAR-NK cell approach for HIV eradication

Arosh S. Perera Molligoda Arachchige; Arosh S. Perera Molligoda Arachchige

doi:10.3934/Allergy.2021015

AIMS Allergy and Immunology

2021, Volume 5, Issue 3: 192-194. doi: 10.3934/Allergy.2021015

Previous Article Next Article

Letter

A universal CAR-NK cell approach for HIV eradication

Arosh S. Perera Molligoda Arachchige ^,

Department of Biomedical Sciences, Humanitas University, Milan, Italy

Received: 11 August 2021 Accepted: 13 August 2021 Published: 17 August 2021

No therapeutic drug has been able to completely eradicate HIV-infection so far, even after decades of research. A major challenge in HIV drug development is its immense diversity. NK cells are well-known for their anti-viral and anti-tumor functions. Since recently, NK cells have gained interest of researchers as they have paved the way for novel approaches in controlling HIV-infection supported by promising results observed in cancer immunotherapy trials. Here we report an anti-DNP CAR-NK cell approach introduced by Lim et al. capable of recognizing 2,4-dinitrophenyl tagged to anti-gp160 antibodies, which seemingly provides an effective solution to counteract HIV variability.
- CAR,
- NK,
- HIV,
- therapy,
- universal,
- DNP-conjugated antibodies
Citation: Arosh S. Perera Molligoda Arachchige. A universal CAR-NK cell approach for HIV eradication[J]. AIMS Allergy and Immunology, 2021, 5(3): 192-194. doi: 10.3934/Allergy.2021015

Related Papers:

Abstract

No therapeutic drug has been able to completely eradicate HIV-infection so far, even after decades of research. A major challenge in HIV drug development is its immense diversity. NK cells are well-known for their anti-viral and anti-tumor functions. Since recently, NK cells have gained interest of researchers as they have paved the way for novel approaches in controlling HIV-infection supported by promising results observed in cancer immunotherapy trials. Here we report an anti-DNP CAR-NK cell approach introduced by Lim et al. capable of recognizing 2,4-dinitrophenyl tagged to anti-gp160 antibodies, which seemingly provides an effective solution to counteract HIV variability.

Conflict of interest

The author declare no conflict of interest in this paper.

References

[1]	Deeks SG, Overbaugh J, Phillips A, et al. (2015) HIV infection. Nat Rev Dis Primers 1: 15035. doi: 10.1038/nrdp.2015.35
[2]	Shimasaki N, Jain A, Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discov 19: 200-218. doi: 10.1038/s41573-019-0052-1
[3]	Perera Molligoda Arachchige AS (2021) Human NK cells: From development to effector functions. Innate Immun 27: 212-229. doi: 10.1177/17534259211001512
[4]	Ram DR, Manickam C, Lucar O, et al. (2019) Adaptive NK cell responses in HIV/SIV infections: A roadmap to cell-based therapeutics? J Leukocyte Biol 105: 1253-1259. doi: 10.1002/JLB.MR0718-303R
[5]	Lim RM, Rong L, Zhen A, et al. (2020) A universal CAR-NK cell targeting various epitopes of HIV-1 gp160. ACS Chem Biol 15: 2299-2310. doi: 10.1021/acschembio.0c00537
[6]	Farah FS (1973) Natural antibodies specific to the 2, 4-dinitrophenyl group. Immunology 25: 217.
[7]	Asai O, Longo DL, Tian ZG, et al. (1998) Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 101: 1835-1842. doi: 10.1172/JCI1268
[8]	Deng K, Pertea M, Rongvaux A, et al. (2015) Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517: 381-385. doi: 10.1038/nature14053
[9]	Wei X, Decker JM, Wang S, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312. doi: 10.1038/nature01470

Reader Comments

Your name:*

Email:*
© 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)